These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 27067962)

  • 1. Primary prophylaxis of VTE in cancer outpatients.
    Imberti D; Benedetti R
    Thromb Res; 2016 Apr; 140 Suppl 1():S103-8. PubMed ID: 27067962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation and validation of a risk stratification method at The Ottawa Hospital to guide thromboprophylaxis in ambulatory cancer patients at intermediate-high risk for venous thrombosis.
    Lustig DB; Rodriguez R; Wells PS
    Thromb Res; 2015 Dec; 136(6):1099-102. PubMed ID: 26260645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venous thromboembolism in cancer patients.
    Deng A; Galanis T; Graham MG
    Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylaxis of venous thromboembolism in cancer patients.
    Frere C; Doucet L; Farge D
    Expert Rev Hematol; 2016 Jun; 9(6):535-9. PubMed ID: 27031534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Anticoagulation on Venous Thromboembolism Primary Prophylaxis in Low- to Intermediate-Risk Ambulatory Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Alizadehasl A; Hosseini Jebelli SF; Forati S; Afsari Zonooz Y; Mohseni Salehi M; Hakimian H; Yalameh Aliabadi R; Yalameh Aliabadi A
    Asian Pac J Cancer Prev; 2024 Jul; 25(7):2237-2246. PubMed ID: 39068554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing the use of thromboprophylaxis in cancer outpatients in clinical practice: A prospective study.
    Panizo E; Alfonso A; García-Mouriz A; López-Picazo JM; Gil-Bazo I; Hermida J; Páramo JA; Lecumberri R
    Thromb Res; 2015 Dec; 136(6):1145-8. PubMed ID: 26475407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Model for Guideline Implementation to Prevent Cancer-Associated Thrombosis: Venous Thromboembolism Prevention in the Ambulatory Cancer Clinic.
    Holmes CE; Ades S; Gilchrist S; Douce D; Libby K; Rogala B; Parenteau E; Cushman M; Holm AK
    JCO Oncol Pract; 2020 Sep; 16(9):e868-e874. PubMed ID: 32267798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New strategies of VTE prevention in cancer patients.
    Verso M; Agnelli G
    Thromb Res; 2014 May; 133 Suppl 2():S128-32. PubMed ID: 24862133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between cancer types, cancer treatments, and venous thromboembolism in medical oncology patients.
    Streiff MB
    Clin Adv Hematol Oncol; 2013 Jun; 11(6):349-57. PubMed ID: 24472803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Khorana vs. ONKOTEV predictive score to individualize anticoagulant prophylaxis in outpatients with cancer.
    Cella CA; Djulbegovic B; Hozo I; Lordick F; Bagnardi V; Frassoni S; Gervaso L; Fazio N
    Eur J Cancer; 2024 Sep; 209():114234. PubMed ID: 39142210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials.
    Thaler J; Ay C; Pabinger I
    Thromb Haemost; 2012 Dec; 108(6):1042-8. PubMed ID: 22836491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary venous thromboembolism prophylaxis in ambulatory cancer patients.
    Aikens GB; Rivey MP; Hansen CJ
    Ann Pharmacother; 2013 Feb; 47(2):198-209. PubMed ID: 23386067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.
    Lyman GH; Khorana AA; Falanga A; Clarke-Pearson D; Flowers C; Jahanzeb M; Kakkar A; Kuderer NM; Levine MN; Liebman H; Mendelson D; Raskob G; Somerfield MR; Thodiyil P; Trent D; Francis CW;
    J Clin Oncol; 2007 Dec; 25(34):5490-505. PubMed ID: 17968019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial.
    Khorana AA; Francis CW; Kuderer NM; Carrier M; Ortel TL; Wun T; Rubens D; Hobbs S; Iyer R; Peterson D; Baran A; Kaproth-Joslin K; Lyman GH
    Thromb Res; 2017 Mar; 151():89-95. PubMed ID: 28139259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thromboembolism prevention in cancer outpatients.
    Khorana AA
    J Natl Compr Canc Netw; 2013 Nov; 11(11):1431-8. PubMed ID: 24225974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary prevention of venous thromboembolism in ambulatory cancer patients: recent advances and practical implications.
    Harrigan AM; Carrier M; Wang TF
    Pol Arch Intern Med; 2024 Jun; 134(6):. PubMed ID: 38661514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thromboprophylaxis in non-surgical cancer patients.
    Cohen AT; Gurwith MM; Dobromirski M
    Thromb Res; 2012 Apr; 129 Suppl 1():S137-45. PubMed ID: 22682125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism and cancer.
    MacLellan DG; Richardson A; Stoodley MA
    ANZ J Surg; 2012 May; 82(5):294-8. PubMed ID: 22507393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre.
    Pelletier R
    J Oncol Pharm Pract; 2021 Jun; 27(4):911-918. PubMed ID: 33757321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Thrombosis in Cancer: Clinical Factors and Role of Primary Prophylaxis.
    Roopkumar J; Khorana AA
    Cancer Treat Res; 2019; 179():55-68. PubMed ID: 31317480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.